IBDEI1UG ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31316,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31316,1,2,0)
 ;;=2^Repair of Nail Bed
 ;;^UTILITY(U,$J,358.3,31316,1,3,0)
 ;;=3^11760
 ;;^UTILITY(U,$J,358.3,31317,0)
 ;;=11765^^125^1581^11^^^^1
 ;;^UTILITY(U,$J,358.3,31317,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31317,1,2,0)
 ;;=2^Wedge Excision of Skin Nail Fold
 ;;^UTILITY(U,$J,358.3,31317,1,3,0)
 ;;=3^11765
 ;;^UTILITY(U,$J,358.3,31318,0)
 ;;=11055^^125^1582^1^^^^1
 ;;^UTILITY(U,$J,358.3,31318,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31318,1,2,0)
 ;;=2^Trim Skin Lesion, Single Lesion
 ;;^UTILITY(U,$J,358.3,31318,1,3,0)
 ;;=3^11055
 ;;^UTILITY(U,$J,358.3,31319,0)
 ;;=11056^^125^1582^2^^^^1
 ;;^UTILITY(U,$J,358.3,31319,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31319,1,2,0)
 ;;=2^Trim Skin Lesion,2-4 Lesions
 ;;^UTILITY(U,$J,358.3,31319,1,3,0)
 ;;=3^11056
 ;;^UTILITY(U,$J,358.3,31320,0)
 ;;=11057^^125^1582^3^^^^1
 ;;^UTILITY(U,$J,358.3,31320,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31320,1,2,0)
 ;;=2^Trim Skin Lesions, Over 4
 ;;^UTILITY(U,$J,358.3,31320,1,3,0)
 ;;=3^11057
 ;;^UTILITY(U,$J,358.3,31321,0)
 ;;=17000^^125^1583^1^^^^1
 ;;^UTILITY(U,$J,358.3,31321,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31321,1,2,0)
 ;;=2^Destruction, all benign or premalignant lesions other than skin tags or cutaneous vascular proliferative lesion; 1st lesion
 ;;^UTILITY(U,$J,358.3,31321,1,3,0)
 ;;=3^17000
 ;;^UTILITY(U,$J,358.3,31322,0)
 ;;=17003^^125^1583^2^^^^1
 ;;^UTILITY(U,$J,358.3,31322,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31322,1,2,0)
 ;;=2^Destruction, all benign or premalignant lesions other than skin tags or cutaneous vascular proliferative lesions; 2nd-14th lesion, each
 ;;^UTILITY(U,$J,358.3,31322,1,3,0)
 ;;=3^17003
 ;;^UTILITY(U,$J,358.3,31323,0)
 ;;=17004^^125^1583^3^^^^1
 ;;^UTILITY(U,$J,358.3,31323,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31323,1,2,0)
 ;;=2^Destruction, all benign or premalignant lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions
 ;;^UTILITY(U,$J,358.3,31323,1,3,0)
 ;;=3^17004
 ;;^UTILITY(U,$J,358.3,31324,0)
 ;;=17110^^125^1583^4^^^^1
 ;;^UTILITY(U,$J,358.3,31324,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31324,1,2,0)
 ;;=2^Destruction, of flat warts, molluscum contagiosum, or milia; up to 14 lesions
 ;;^UTILITY(U,$J,358.3,31324,1,3,0)
 ;;=3^17110
 ;;^UTILITY(U,$J,358.3,31325,0)
 ;;=17111^^125^1583^5^^^^1
 ;;^UTILITY(U,$J,358.3,31325,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31325,1,2,0)
 ;;=2^Destruction, of flat warts, molluscum contagiosum, or milia; 15 or more lesions
 ;;^UTILITY(U,$J,358.3,31325,1,3,0)
 ;;=3^17111
 ;;^UTILITY(U,$J,358.3,31326,0)
 ;;=17250^^125^1583^6^^^^1
 ;;^UTILITY(U,$J,358.3,31326,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31326,1,2,0)
 ;;=2^Chemical cauterization of granulation tissue
 ;;^UTILITY(U,$J,358.3,31326,1,3,0)
 ;;=3^17250
 ;;^UTILITY(U,$J,358.3,31327,0)
 ;;=11400^^125^1584^1^^^^1
 ;;^UTILITY(U,$J,358.3,31327,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31327,1,2,0)
 ;;=2^Exc Benign Lesion-Trunk,Legs;0.5cm or less
 ;;^UTILITY(U,$J,358.3,31327,1,3,0)
 ;;=3^11400
 ;;^UTILITY(U,$J,358.3,31328,0)
 ;;=11401^^125^1584^2^^^^1
 ;;^UTILITY(U,$J,358.3,31328,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31328,1,2,0)
 ;;=2^Exc Benign Lesion-Trunk,Legs;0.6cm-1.0cm
 ;;^UTILITY(U,$J,358.3,31328,1,3,0)
 ;;=3^11401
 ;;^UTILITY(U,$J,358.3,31329,0)
 ;;=11402^^125^1584^3^^^^1
 ;;^UTILITY(U,$J,358.3,31329,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,31329,1,2,0)
 ;;=2^Exc Benign Lesion-Trunk,Legs;1.1cm-2.0cm
